Professor Kausik K Ray (Imperial College London, London, UK) discuss the effect of BET Protein Inhibition With Apabetalone on Cardiovascular Outcomes in Patients With Acute Coronary Syndrome and Diabetes - Results of the BETonMACE Trial.
A Phase III multi-center, double-blind, randomized, parallel group, placebo-controlled clinical trial in high-risk type 2 diabetes mellitus (T2DM) subjects with coronary artery disease (CAD) to determine whether Bromodomain Extraterminal Domain (BET) inhibition treatment With RVX000222 increases the time to major adverse cardiovascular events (MACE).
1. What is apabetalone and why was BETonMACE needed
2. Could you describe the study design, inclusion criteria and the endpoints studied?
3. What were the outcomes?
4. What lessons have you learned about apabetalone and are further analyses planned?
Filmed on site at AHA 2019 by Radcliffe Cardiology